Browse our resources

Health provider inflation hidden by network averages leaves health reinsurers and cedants underpricing risk. Here is the executive-level diagnosis of that blind spot.

2026-09-08

Health provider inflation hidden by network averages raises capital allocation questions health reinsurers cannot answer with a blended discount figure alone.

2026-09-08

Boards overseeing health provider inflation hidden by network averages need a remediate, reprice, reduce, or exit test for underperforming provider exposures. Here is how to run it.

2026-09-08

Health provider inflation hidden by network averages forces leadership trade-offs between network breadth, price certainty, and treaty profitability. Here is how to weigh them.

2026-09-08

Catching longevity concentration across pension transactions before it becomes a capital problem takes an operating process built for aggregation, not just per-deal review. Here is how to build it.

2026-09-08

Longevity concentration across pension transactions builds quietly as large deals stack onto a small pool of reinsurers. Here is why the risk gets missed until it is already large.

2026-09-08

Boards overseeing life and health reinsurance need an explicit risk-appetite limit for longevity concentration across pension transactions, not just trust in transaction-level review. Here is the test to apply.

2026-09-08

Longevity concentration across pension transactions forces executive teams to decide how much correlated exposure to one demographic driver is acceptable. Here is the framework for that call.

2026-09-08

Longevity concentration across pension transactions turns a single demographic surprise into a correlated capital event. Here is how that earnings volatility builds and how to measure it.

2026-09-08

Solving medical trend outpacing treaty economics takes more than a diagnosis, it takes operating controls that catch the gap before it reaches the executive committee. Here is what those controls look like.

2026-09-08

Medical trend outpacing treaty economics quietly erodes life and health reinsurance margins long before a loss ratio confirms the damage. Here is how to spot the gap early.

2026-09-08

Boards overseeing life and health reinsurance need a clear answer to what breaks first if medical trend outpacing treaty economics continues unchecked. Here is the governance question worth asking now.

2026-09-08

Medical trend outpacing treaty economics forces a decision only executives can make: reprice, restructure, or hold. Here is the framework CFOs and CROs need to make that call.

2026-09-08

Medical trend outpacing treaty economics does more than shrink margin, it quietly ties up capital that could otherwise support new business. Here is how to measure the drag.

2026-09-08

Mortality improvement assumptions after structural shocks need an operating fix, not just a strategic decision. Here is the practical process for catching and correcting drift before the next renewal.

2026-09-08

Mortality improvement assumptions after structural shocks quietly erode margin and capital in life and health reinsurance long after the acute event has passed. Here is how to size the real cost.

2026-09-08

Mortality improvement assumptions after structural shocks deserve direct board scrutiny in life and health reinsurance. Here are the questions a board should be asking and why.

2026-09-08

Mortality improvement assumptions after structural shocks stop matching real experience because the tables were built for calmer health and social conditions. Here is why the gap opens and how reinsurers should read it.

2026-09-08